Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Where Does GLP-1 Fit In
Lilly's phase 3 program evaluates efficacy and safety in obesity and overweight, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis pain, cardiovascular and renal outcomes, chronic low back pain, and metabolic liver disease [1]
REDEFINE 1 and REDEFINE 2 ran 68 weeks, with the first ~16 weeks dedicated to dose titration
Even patients with obesity-related conditions like sleep apnea or hypertension frequently face denials based on the logic that weight loss alone is not a medical necessity in their plan's view
US$ 26.58
US$ 28.03
US$ 28.47
US$ 24.27
US$ 22.37
US$ 24.88
